oteseconazole
Sign in to saveOteseconazole, a novel tetrazole containing orally bioavailable and selective inhibitor of fungal lanosterol 14α-demethylase (CYP51), has shown promising efficacy in the treatment of recurrent vulvovaginal candidiasis (RVVC).
~3 min read
Encyclopedic overview
6 sectionsContents
- Society and culture
- Names
- Mechanism of action
- Adverse effect and interaction
- References
- External links
Oteseconazole, a novel tetrazole containing orally bioavailable and selective inhibitor of fungal lanosterol 14α-demethylase (CYP51), has shown promising efficacy in the treatment of recurrent vulvovaginal candidiasis (RVVC).
Marketed under the brand name Vivjoa, this medication was developed by Mycovia Pharmaceuticals and received approval for medicinal use from United States Food and Drug Administration (US FDA) in April 2022.
Excerpted from Wikipedia’s “oteseconazole” article, available under the CC BY-SA 4.0 licence.